Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia

References

• Aggarwal P, Hall JB, McLeland CB, et al. (2009). Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61:428–37
   PubMed Web of Science ®Google Scholar
• Agrawal A, Deo R, Wang GD, et al. (2008). Nanometer-scale mapping and single-molecule detection with color-coded nanoparticle probes. Proc Natl Acad Sci 105:3298–303
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. (2004). Drug delivery systems: entering the mainstream. Science 303:1818–22
   PubMed Web of Science ®Google Scholar
• Ando M, Lundkvist I, Bergstrom J, Lindholm B. (1996). Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients. Kidney Int 49:773–80
   PubMed Web of Science ®Google Scholar
• Ansari KA, Vavia PR, Trotta F, Cavalli R. (2011). Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. Aaps Pharmscitech 12:279–86
   PubMed Web of Science ®Google Scholar
• Ausar S, Morcillo M, Leon A, et al. (2003). Improvement of HDL-and LDL-cholesterol levels in diabetic subjects by feeding bread containing chitosan. J Med Food 6:397–9
   PubMedGoogle Scholar
• Bal T, Murthy PN, Sengupta S. (2012). Preparation and evaluation of mucoadhesive simvastatin microcapsules using orifice gelation technique. Asian J Pharm 6:74–84
   Google Scholar
• Barnard ND, Scialli AR, Bertron P, et al. (2000). Effectiveness of a low-fat vegetarian diet in altering serum lipids in healthy premenopausal women. Am J Cardiol 85:969–72
   PubMed Web of Science ®Google Scholar
• Bathool A, Vishakante GD, Khan MS, Shivakumar H. (2012). Development and characterization of atorvastatin calcium loaded chitosan nanoparticles for sustain drug delivery. Adv Mater Lett 3:466–70
   Google Scholar
• Bertacche V, Lorenzi N, Nava D, et al. (2006). Host–guest interaction study of resveratrol with natural and modified cyclodextrins. J Incl Phenom Macrocycl Chem 55:279–87
   Web of Science ®Google Scholar
• Bhise SD. (2011). Ternary solid dispersions of fenofibrate with Poloxamer 188 and TPGS for enhancement of solubility and bioavailability. Int J Res Pharm Biomed Sci 2:583–95
   Google Scholar
• Brahm A, Hegele RA. (2013). Hypertriglyceridemia. Nutrients 5:981–1001
   PubMed Web of Science ®Google Scholar
• Brook RD, Franklin B, Cascio W, et al. (2004). Air pollution and cardiovascular disease A statement for healthcare professionals from the expert panel on population and prevention science of the American Heart Association. Circulation 109:2655–71
   PubMed Web of Science ®Google Scholar
• Chan WC, Nie S. (1998). Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 281:2016–18
   PubMed Web of Science ®Google Scholar
• Chen C-C, Tsai T-H, Huang Z-R, Fang J-Y. (2010). Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74:474–82
   PubMed Web of Science ®Google Scholar
• Chen J, Deng J, Zhang Y, et al. (2014). Lipid-lowering ef fects of Danhong injection on hyperl ipidemia rats. J Ethnopharmacol pii: S0378-8741(14)00298-0. doi: 10.1016/j.jep.2014.04.023
   Web of Science ®Google Scholar
• Chen L, Liang B, Froese D, et al. (1997). Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J Lipid Res 38:546–53
   PubMed Web of Science ®Google Scholar
• Chingunpituk J. (2011). Nanosuspension technology for drug delivery. Walailak J Sci Technol 4:139–53
   Google Scholar
• Cho K, Wang X, Nie S, Shin DM. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–16
   PubMed Web of Science ®Google Scholar
• Colletti RB, Roff NK, Neufeld EJ, et al. (1993). Niacin treatment of hypercholesterolemia in children. Pediatrics 92:78–82
   PubMed Web of Science ®Google Scholar
• Dailey L, Jekel N, Fink L, et al. (2006). Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 215:100–8
   PubMed Web of Science ®Google Scholar
• Davis ME, Shin DM. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–82
   PubMed Web of Science ®Google Scholar
• De La Isla A, Brostow W, Bujard B, et al. (2003). Nanohybrid scratch resistant coatings for teeth and bone viscoelasticity manifested in tribology. Mater Res Innov 7:110–14
   Web of Science ®Google Scholar
• Deepa P, Varalakshmi P. (2005). Atheroprotective effect of exogenous heparin-derivative treatment on the aortic disturbances and lipoprotein oxidation in hypercholesterolemic diet fed rats. Clin Chim Acta 355:119–30
   PubMed Web of Science ®Google Scholar
• Dixit RP, Nagarsenker M. (2008). Formulation and in vivo evaluation of self-nanoemulsifying granules for oral delivery of a combination of ezetimibe and simvastatin. Drug Dev Ind Pharm 34:1285–96
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. (2008). Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 5:487–95
   PubMed Web of Science ®Google Scholar
• Edelstein R, Tamanaha C, Sheehan P, et al. (2000). The BARC biosensor applied to the detection of biological warfare agents. Biosens Bioelectron 14:805–13
   PubMed Web of Science ®Google Scholar
• Ehnholm C, Investigators DAIS. (2001). Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905–10
   PubMed Web of Science ®Google Scholar
• Emerich DF, Thanos CG. (2006). The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol Eng 23:171–84
   PubMedGoogle Scholar
• Fuhrman B, Koren L, Volkova N, et al. (2002). Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164:179–85
   PubMed Web of Science ®Google Scholar
• Gao X, Cui Y, Levenson RM, et al. (2004). In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22:969–76
   PubMed Web of Science ®Google Scholar
• Geho DH, Lahar N, Ferrari M, et al. (2004). Opportunities for nanotechnology-based innovation in tissue proteomics. Biomed Microdev 6:231–9
   PubMed Web of Science ®Google Scholar
• Giepmans BN, Deerinck TJ, Smarr BL, et al. (2005). Correlated light and electron microscopic imaging of multiple endogenous proteins using Quantum dots. Nat Methods 2:743–9
   PubMed Web of Science ®Google Scholar
• Hata Y, Nakajima K. (1999). Life-style and serum lipids and lipoproteins. J Atheroscler Thromb 7:177–97
   Google Scholar
• Haunstetter A, Izumo S. (1998). Apoptosis basic mechanisms and implications for cardiovascular disease. Circ Res 82:1111–29
   PubMed Web of Science ®Google Scholar
• Hegele RA. (2009). Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 10:109–21
   PubMed Web of Science ®Google Scholar
• Hegele RA, Ban MR, Hsueh N, et al. (2009). A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Human Mol Genet 18:4189–94
   PubMed Web of Science ®Google Scholar
• Hogue J-C, Lamarche B, Tremblay AJ, et al. (2008). Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 57:380–6
   PubMed Web of Science ®Google Scholar
• Huang L, Peng Z, Guo Y, Porter AL. (2010). Identifying the emerging roles of nanoparticles in biosensors. J Bus Chem 7:15–30
   Google Scholar
• Ikewaki K, Tohyama J-I, Nakata Y, et al. (2003). Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance study. J Atheroscler Thromb 11:278–85
   Google Scholar
• Ito A, Shinkai M, Honda H, Kobayashi T. (2005). Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 100:1–11
   PubMed Web of Science ®Google Scholar
• Jain K. (2005). Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 4:645–50
   PubMed Web of Science ®Google Scholar
• Joshi N, Grinstaff M. (2008). Applications of dendrimers in tissue engineering. Curr Top Med Chem 8:1225–36
   PubMed Web of Science ®Google Scholar
• Kim M-S, Jin S-J, Kim J-S, et al. (2008). Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 69:454–65
   PubMed Web of Science ®Google Scholar
• Kiortsis D, Millionis H, Bairaktari E, Elisaf M. (2000). Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol 56:631–5
   PubMed Web of Science ®Google Scholar
• Klop B, Verseyden C, Ribalta J, et al. (2013). MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: effects of treatment with atorvastatin. Clín Investig Arterioscler 26:49–57
   PubMedGoogle Scholar
• Kolovou GD, Anagnostopoulou K, Cokkinos DV. (2005). Pathophysiology of dyslipidemia in the metabolic syndrome. Postgrad Med J 81:358–66
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. (2006). Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58:342–74
   PubMed Web of Science ®Google Scholar
• Kraitchman DL, Heldman AW, Atalar E, et al. (2003). In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107:2290–3
   PubMed Web of Science ®Google Scholar
• Kreuter J. (1994). Colloidal drug delivery systems. New York: CRC Press
   Google Scholar
• Kumar KS, Bhowmik D, Srivastava S, et al. (2012a). Sustained release drug delivery system potential. Pharm Innov 1:48–60
   Google Scholar
• Kumar PP, Gayatri P, Sunil R, et al. (2012b). Atorvastatin loaded solid lipid nanoparticles: formulation, optimization, and in vitro characterization. Int Organ Sci Res J Pharm 2:23–32
   PubMedGoogle Scholar
• Kwiterovich PO Jr. (1998). State-of-the-art update and review: clinical trials of lipid-lowering agents. Am J Cardiol 82:3U–17U
   PubMed Web of Science ®Google Scholar
• Lamuela-Raventos RM, Romero-Perez AI, Waterhouse AL, De La Torre-Boronat MC. (1995). Direct HPLC analysis of cis-and trans-resveratrol and piceid isomers in Spanish red Vitis vinifera wines. J Agric Food Chem 43:281–3
   Web of Science ®Google Scholar
• LaVan DA, Lynn DM, Langer R. (2002). Moving smaller in drug discovery and delivery. Nat Rev Drug Discov 1:77–84
   PubMed Web of Science ®Google Scholar
• Mahtab R, Rogers JP, Murphy CJ. (1995). Protein-sized quantum dot luminescence can distinguish between “straight”, “bent”, and “kinked” oligonucleotides. J Am Chem Soc 117:9099–100
   Web of Science ®Google Scholar
• Maki KC, Orloff DG, Nicholls SJ, et al. (2013). A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther 35:1400–11. e1403
   PubMed Web of Science ®Google Scholar
• Mäkinen PI, Ylä-Herttuala S. (2013). Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis. Curr Opin Lipidol 24:116–22
   PubMed Web of Science ®Google Scholar
• Malakar J. (2012). Nanosuspension: a nano-heterogeneous carrier for drug delivery system. Int J Pharm Biol Arch 3:4–13
   Google Scholar
• Maximov V, Reukov V, Barry J, et al. (2010). Protein–nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia. Nanotechnology 21:265103. http://iopscience.iop.org/0957-4484/21/26/265103/pdf/0957-4484_21_26_265103.pdf
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Ose L, Marais AD. (2003). Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 143:74–80
   PubMed Web of Science ®Google Scholar
• Meena A, Ratnam DV, Chandraiah G, et al. (2008). Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure® in treating hyperlipidemia. Lipids 43:231–41
   PubMed Web of Science ®Google Scholar
• Mittal G, Chandraiah G, Ramarao P, Kumar MR. (2009). Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic rat model. Pharm Res 26:218–23
   PubMed Web of Science ®Google Scholar
• Nair R, Varghese SH, Nair BG, et al. (2010). Nanoparticulate material delivery to plants. Plant Sci 179:154–63
   Web of Science ®Google Scholar
• Nam J-M, Thaxton CS, Mirkin CA. (2003). Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301:1884–6
   PubMed Web of Science ®Google Scholar
• Ohno K, Mori C, Akashi T, et al. (2013). Fabrication of contrast agents for magnetic resonance imaging from polymer-brush-afforded iron oxide magnetic nanoparticles prepared by surface-initiated living radical polymerization. Biomacromolecules 14:3453–62
   PubMed Web of Science ®Google Scholar
• Ornish D, Scherwitz LW, Billings JH, et al. (1998). Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280:2001–7
   PubMed Web of Science ®Google Scholar
• Ostanina E, Varlamov V, Yakovlev G. (2008). Inhibition of lipase activity by low-molecular-weight chitosan. Appl Biochem Microbiol 44:32–7
   Web of Science ®Google Scholar
• Pande S, Kshirsagar M, Chandewar A. (2011). Ion exchange resins pharmaceutical applications and recent advancement. Int J Adv Pharm Sci 2:8–16
   Google Scholar
• Pankhurst QA, Connolly J, Jones S, Dobson J. (2003). Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 36:R167–R181
   Web of Science ®Google Scholar
• Parak WJ, Boudreau R, Le Gros M, et al. (2002). Cell motility and metastatic potential studies based on quantum dot imaging of phagokinetic tracks. Adv Mater 14:882–885
   Web of Science ®Google Scholar
• Parmar KR, Shah SR, Sheth NR. (2011). Studies in dissolution enhancement of ezetimibe by solid dispersions in combination with a surface adsorbent. Dissolut Technol 18:55–61
   Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–60
   PubMed Web of Science ®Google Scholar
• Pelkman CL, Fishell VK, Maddox DH, et al. (2004). Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women. Am J Clin Nutr 79:204–12
   PubMed Web of Science ®Google Scholar
• Prasad K, Kalra J. (1993). Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J 125:958–73
   PubMed Web of Science ®Google Scholar
• Ratnam DV, Chandraiah G, Meena A, et al. (2009). The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q 10 ameliorates hyperlipidemia in high fat diet fed rats. J Nanosci Nanotechnol 9:6741–6
   PubMed Web of Science ®Google Scholar
• Reiner Z, Tedeschi-Reiner E. (2006). Th-W47: 2 Atherosclerosis – a paradox of Eastern European countries. Atheroscler Suppl 7:461. doi: 10.1016/S1567-5688(06)81854-4
   Web of Science ®Google Scholar
• Romero-Pérez AI, Ibern-Gómez M, Lamuela-Raventós RM, de la Torre-Boronat MC. (1999). Piceid, the major resveratrol derivative in grape juices. J Agric Food Chem 47:1533–6
   PubMed Web of Science ®Google Scholar
• Rozman D, Monostory K. (2010). Perspectives of the non-statin hypolipidemic agents. Pharmacol Ther 127:19–40
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Labhasetwar V. (2003). Nanotech approaches to drug delivery and imaging. Drug Discov Today 8:1112–20
   PubMed Web of Science ®Google Scholar
• Sarkar S, Sonkar R, Bhatia G, Tadigoppula N. (2014). Synthesis of new N-acryl-1-amino-2-phenylethanol and N-acyl-1-amino-3-aryloxypropanols and evaluation of their antihyperlipidemic, LDL-oxidation and antioxidant activity. Eur J Med Chem 80:135–44
   PubMed Web of Science ®Google Scholar
• Sathali H, Abdul A, Nisha N. (2013). Development of solid lipid nanoparticles of rosuvastatin calcium. J Pharm Res 6:536–48
   Google Scholar
• Seenivasan A, Panda T, Théodore T. (2011). Lovastatin nanoparticle synthesis and characterization for better drug delivery. Open Biotechnol J 5:28–32
   Google Scholar
• Sertić M, Mornar A, Nigović B. (2014). A rapid profiling of hypolipidemic agents in dietary supplements by direct injection tandem mass spectrometry. J Food Composit Anal 34:68–74
   Web of Science ®Google Scholar
• Shepherd J. (1989). Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. Cardiology 76:65–74
   PubMed Web of Science ®Google Scholar
• Simons LA. (2002). Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 90:737–40
   PubMed Web of Science ®Google Scholar
• Singh I, Rehni A, Kalra R, et al. (2008). Dendrimers and their pharmaceutical applications a review. Die Pharm Int J Pharm Sci 63:491–6
   Google Scholar
• Slack J. (1969). Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. The Lancet 294:1380–2
   Google Scholar
• Soh J, Iqbal J, Queiroz J, et al. (2013). MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 19:892–900
   PubMed Web of Science ®Google Scholar
• Srikanth M, Sunil S, Rao N, et al. (2010). Ion-exchange resins as controlled drug delivery carriers. J Sci Res 2:597–611
   Google Scholar
• Staels B, Dallongeville J, Auwerx J, et al. (1998). Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088–93
   PubMed Web of Science ®Google Scholar
• Starc TJ. (2001). Management of hyperlipidemia in children. Prog Pediatr Cardiol 12:205–13
   PubMedGoogle Scholar
• Sudhop T, Lütjohann D, Kodal A, et al. (2002). Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106:1943–8
   PubMed Web of Science ®Google Scholar
• Sukanya M, Kishore VS. (2012). Design and development of chronopharmaceutical drug delivery of simvastatin. J Chem Pharm Res 4:3195–200
   Google Scholar
• Sun M, Zhai X, Xue K, et al. (2011). Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats. Eur J Pharm Sci 43:132–40
   PubMed Web of Science ®Google Scholar
• Tao Y, Zhang H, Gao B, et al. (2011). Water-soluble chitosan nanoparticles inhibit hypercholesterolemia induced by feeding a high-fat diet in male Sprague–Dawley rats. J Nanomater 2011:6
   Web of Science ®Google Scholar
• Till MC, Simkin MM, Maebius S. (2005). Nanotech meets the FDA: a success story about the first nanoparticulate drugs approved by the FDA, HeinOnline. Gale Group, Farmington Hills, Michigan
   Google Scholar
• van Lennep JER, Westerveld HT, Erkelens DW, van der Wall EE. (2002). Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 53:538–49
   PubMed Web of Science ®Google Scholar
• Villanova JG, Diéuez Lucena JL, Arcás NF, Engel AR. (1996). Increased expression of scavenger receptor type I gene in human peripheral blood from hyperlipidemic patients determined by quantitative additive RT-PCR. Biochim Biophys Acta Lipids Lipid Metab 1300:135–41
   PubMed Web of Science ®Google Scholar
• Wang S, Mamedova N, Kotov NA, et al. (2002). Antigen/antibody immunocomplex from CdTe nanoparticle bioconjugates. Nano Lett 2:817–22
   Web of Science ®Google Scholar
• Weissleder R, Elizondo G, Wittenberg J, et al. (1990). Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175:489–93
   PubMed Web of Science ®Google Scholar
• West JL, Halas NJ. (2000). Applications of nanotechnology to biotechnology: commentary. Curr Opin Biotechnol 11:215–17
   PubMed Web of Science ®Google Scholar
• Witztum J. (1996). Drugs used in the treatment of hyperdyslipidemias. The pharmacological basis of therapeutics. New York: McGraw-Hill, 875–97
   Google Scholar
• Zhang H-L, Tao Y, Guo J, et al. (2011). Hypolipidemic effects of chitosan nanoparticles in hyperlipidemia rats induced by high fat diet. Int Immunopharmacol 11:457–61
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu J, Li L, Xia W. (2008). Dietary chitosan improves hypercholesterolemia in rats fed high-fat diets. Nutr Res 28:383–90
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bu H, Gao Z, et al. (2010). The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int J Pharm 394:147–53
   PubMed Web of Science ®Google Scholar